August 16, 2017. TWi Pharmaceuticals, Inc. (“TWi”) (Stock Ticker: 4180.TT) TWi Pharmaceuticals, Inc. today confirmed that the ruling related to TWi's generic version of Supernus's Oxtellar XR® (oxcarbazepine extended-release tablets) patent challenge made by United States District Court for the District of New Jersey is in favor of Supernus. TWi respectfully disagrees with the Court's decision and intends to appeal the determination. TWi's ANDA application is pending before the United States Food and Drug Administration.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com

Contact :
Angela Luan
Investor Relations
Email: angela.luan@twipharma.com